Lakefront Biotherapeutics Stock Forecast
NASDAQ: LKFTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
LKFT analyst consensus
Consensus (6 analysts)
hold
Avg. price target
$30.18+2.27%
- Strong buy 1
- Buy 1
- Hold 3
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Lakefront Biotherapeutics (2026-10-07), 2 rate the stock a buy or strong buy, 3 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $30.18, with a high estimate of $44.05 and a low estimate of $21.28. The average target implies upside of 2.3% from the current price of $29.51.
The spread between the highest and lowest targets is 107.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for LKFT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 17% |
| Buy | 1 | 17% |
| Hold | 3 | 50% |
| Sell | 1 | 17% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $21.28 | -27.89% |
| Average target | $30.18 | +2.27% |
| High target | $44.05 | +49.27% |